ReviewThorax2022
Building a home ventilation programme: population, equipment, delivery and cost.
Review in Thorax, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Global Research Trends in Home Mechanical Ventilation: A Bibliometric Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Preparedness for blackouts in Iberian Peninsula patients using home respiratory therapies.ERJ open research · 2026Article
- Emergency department visits among patients with neuromuscular diseases receiving home mechanical ventilation: a nationwide population-based study.Journal of Yeungnam medical science · 2026Article
- The Consistency of Hypercapnic Respiratory Failure Case Definitions in Electronic Health Record Data.Chest · 2026Article
- Work-Life Perceptions of Danish Personal Care Assistants Working in the Home Mechanical Ventilation Setting-A Survey Study.Scandinavian journal of caring sciences · 2025Article
- Cycling the Breath in Noninvasive Home Ventilation.Journal of clinical medicine · 2024Article
- Highlights from the Respiratory Failure and Mechanical Ventilation Conference 2024.Breathe (Sheffield, England) · 2024Article
- An eight-year follow-up study of Home Invasive Mechanical Ventilation in Finland.BMC pulmonary medicine · 2024Article
- The Role of Obstructive Sleep Apnea in Hypercapnic Respiratory Failure Identified in Critical Care, Inpatient, and Outpatient Settings.Sleep medicine clinics · 2024Review
- Ventilator Weaning in Prolonged Mechanical Ventilation-A Narrative Review.Journal of clinical medicine · 2024Review
- Development and pilot-testing of an evidence-based quality indicator set for home mechanical ventilation care: the OVER-BEAS project.BMC health services research · 2024Article
- Moving from Inpatient to Outpatient or Home Initiation of Non-Invasive Home Mechanical Ventilation.Journal of clinical medicine · 2023Review
- Long-term mechanical ventilation and transitions in care: A narrative review.Chronic respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Home mechanical ventilation (HMV) improves quality of life and survival in patients with neuromuscular disorders (NMD). Developing countries may benefit from published evidence regarding the prevalence, cost of equipment, technical issues and organisation of HMV in NMD, facilitating the development of local turn-key HMV programmes. Unfortunately, such evidence is scattered in the existing literature. We searched Medline for publications in English and French from 2005 to 2020. This narrative review analyses 24 international programmes of HMV. The estimated prevalence (min-max) of HMV is ±7.3/100 000 population (1.2-47), all disorders combined. The prevalence of HMV is associated with the gross domestic product per capita in these 24 countries. The prevalence of NMD is about 30/100 000 population, of which ±10% would use HMV. Nocturnal (8/24 hour), discontinuous (8-16/24 hours) and continuous (>16/24 hours) ventilation is likely to concern about 60%, 20% and 20% of NMD patients using HMV. A minimal budget of about 168€/patient/year (504€/100 000 population), including the cost of equipment solely, should address the cost of HMV equipment in low-income countries. When services and maintenance are included, the budget can drastically increase up to between 3232 and 5760€/patient/year. Emerging programmes of HMV in developing countries reveal the positive impact of international cooperation. Today, at least 12 new middle, and low-income countries are developing HMV programmes. This review with updated data on prevalence, technical issues, cost of equipment and services for HMV should trigger objective dialogues between the stakeholders (patient associations, healthcare professionals and politicians); potentially leading to the production of workable strategies for the development of HMV in patients with NMD living in developing countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.